SNDX Q3 2023 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$56M

Net Income

-$51M

EPS (Diluted)

$-0.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$399M

Total Liabilities

$40M

Stockholders' Equity

$359M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$56M	-$35M	-60.4%
Net Income	-$51M	-$35M	-44.5%